secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2025-04-21T23:59:59+00:00
Accession:  0001140361-25-014642
Event type: leadership
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant CEO Pete Salzmann retires; Eric Venker appointed; IMVT-1402 adds SjD and CLE indications
--------------------------------------------------------------------------------

- Pete Salzmann retired as Immunovant CEO and Director; Eric Venker (Roivant President & COO) appointed CEO; Tiago Girao named CFO.
- IND cleared for IMVT-1402 in Sjögren’s Disease; registrational study expected summer 2025.
- Proof-of-concept study initiated for IMVT-1402 in Cutaneous Lupus Erythematosus (CLE).
- Roivant to lead Immunovant investor relations; cash runway supports through Graves' Disease readout in 2027.
- Robert Susman and Jacob Bauer join Immunovant Board; George Migausky steps down.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036125014642/0001140361-25-014642-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036125014642/ef20047653_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-014642

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer